Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cumberland Pharmaceuticals Inc

NASDAQ: CPIX · Life Sciences · 8 alerts · CIK 1087294

Share price
$5.21Close, Nov 16
Market cap
$78.1M
Shares outstanding
15MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cumberland Pharmaceuticals Inc filings on SEC EDGAR ↗

4:28 PM ET 8-K/A
Clinical Trial Data

Cumberland Pharmaceuticals Clinical Trial Data

Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis (SSc). The study met its primary objective of demonstrating that ifetroban was generally well tolerated with a safety profile consistent with prior experience, though the trial was not powered to detect significant efficacy differences due to limited disease progression in both groups.

Term
12 months
4:41 PM ET 8-K
Clinical Trial Data

Cumberland Pharmaceuticals Clinical Trial Data

Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The submission is supported by Phase 2 FIGHT DMD trial data showing a statistically significant 5.4% improvement in left ventricular ejection fraction (LVEF) compared to a control group. While the FDA expressed concerns regarding the sufficiency of the data package for efficacy requirements, the company is moving forward with the submission following a pre-NDA meeting.

Counterparty
FDA
5:02 PM ET 8-K
Clinical Trial Data

Cumberland Pharmaceuticals Clinical Trial Data

Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc clinical trial evaluating oral ifetroban in patients with systemic sclerosis. The study results supported the safety and tolerability of the drug candidate in this rare disease population.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.